405 Shares in Chemed Co. (NYSE:CHE) Purchased by Semanteon Capital Management LP

Semanteon Capital Management LP purchased a new position in shares of Chemed Co. (NYSE:CHE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 405 shares of the company’s stock, valued at approximately $237,000.

Other hedge funds have also bought and sold shares of the company. SG Americas Securities LLC grew its stake in Chemed by 32.8% during the third quarter. SG Americas Securities LLC now owns 3,290 shares of the company’s stock worth $1,710,000 after buying an additional 813 shares in the last quarter. Golden State Equity Partners grew its stake in Chemed by 29.4% during the third quarter. Golden State Equity Partners now owns 673 shares of the company’s stock worth $350,000 after buying an additional 153 shares in the last quarter. Trinity Street Asset Management LLP grew its stake in Chemed by 3.0% during the third quarter. Trinity Street Asset Management LLP now owns 29,861 shares of the company’s stock worth $15,519,000 after buying an additional 863 shares in the last quarter. Xponance Inc. grew its stake in Chemed by 1.8% during the third quarter. Xponance Inc. now owns 2,974 shares of the company’s stock worth $1,546,000 after buying an additional 54 shares in the last quarter. Finally, Raymond James & Associates grew its stake in Chemed by 2.7% during the third quarter. Raymond James & Associates now owns 64,264 shares of the company’s stock worth $33,398,000 after buying an additional 1,669 shares in the last quarter. 95.85% of the stock is owned by institutional investors.

Chemed Trading Down 2.3 %

CHE opened at $560.31 on Friday. The company’s 50 day moving average is $623.29 and its 200-day moving average is $590.84. Chemed Co. has a 1-year low of $492.84 and a 1-year high of $654.62. The company has a market cap of $8.47 billion, a P/E ratio of 30.16, a PEG ratio of 2.30 and a beta of 0.42.

Chemed (NYSE:CHE) last posted its earnings results on Wednesday, April 24th. The company reported $4.68 EPS for the quarter, missing the consensus estimate of $5.09 by ($0.41). Chemed had a return on equity of 30.52% and a net margin of 12.36%. The business had revenue of $589.23 million for the quarter, compared to analyst estimates of $587.18 million. On average, equities analysts forecast that Chemed Co. will post 21.99 EPS for the current year.

Chemed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Monday, February 26th were issued a dividend of $0.40 per share. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.60 annualized dividend and a yield of 0.29%. Chemed’s payout ratio is 8.61%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CHE shares. StockNews.com downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research note on Friday. Oppenheimer raised their price target on shares of Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a research note on Thursday, February 29th. Finally, Royal Bank of Canada raised their price target on shares of Chemed from $604.00 to $712.00 and gave the company an “outperform” rating in a research note on Monday, March 4th.

Insiders Place Their Bets

In other news, EVP Spencer S. Lee sold 2,000 shares of Chemed stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $641.65, for a total value of $1,283,300.00. Following the completion of the sale, the executive vice president now owns 20,760 shares in the company, valued at approximately $13,320,654. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Spencer S. Lee sold 2,000 shares of Chemed stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $641.65, for a total value of $1,283,300.00. Following the completion of the sale, the executive vice president now owns 20,760 shares of the company’s stock, valued at approximately $13,320,654. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Brian C. Judkins sold 11,158 shares of Chemed stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $645.00, for a total transaction of $7,196,910.00. Following the completion of the sale, the vice president now directly owns 1,422 shares of the company’s stock, valued at approximately $917,190. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,808 shares of company stock worth $10,184,531. 3.32% of the stock is currently owned by insiders.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.